1168 related articles for article (PubMed ID: 18525320)
21. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
Benjamin RS; Blanke CD; Blay JY; Bonvalot S; Eisenberg B
Oncologist; 2006 Jan; 11(1):9-20. PubMed ID: 16401709
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
23. [Imatinib in the GIST therapy: ten years later].
Lopez M
Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
[TBL] [Abstract][Full Text] [Related]
24. [Current aspects of treatment in gastrointestinal stromal tumors (GIST)].
Láng I; Hitre E
Orv Hetil; 2005 May; 146(18 Suppl 1):935-41. PubMed ID: 15921308
[TBL] [Abstract][Full Text] [Related]
25. Surgery for gastrointestinal stromal tumour in the post-imatinib era.
Neuhaus SJ; Clark MA; Hayes AJ; Thomas JM; Judson I
ANZ J Surg; 2005 Mar; 75(3):165-72. PubMed ID: 15777399
[TBL] [Abstract][Full Text] [Related]
26. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
Yeh CN; Chen TW; Tseng JH; Liu YY; Wang SY; Tsai CY; Chiang KC; Hwang TL; Jan YY; Chen MF
J Surg Oncol; 2010 Nov; 102(6):599-603. PubMed ID: 20976730
[TBL] [Abstract][Full Text] [Related]
27. Gastrointestinal stromal tumors and the evolution of targeted therapy.
Sanborn RE; Blanke CD
Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
[TBL] [Abstract][Full Text] [Related]
28. The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST.
An HJ; Ryu MH; Ryoo BY; Sohn BS; Kim KH; Oh ST; Yu CS; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2013 Dec; 20(13):4212-8. PubMed ID: 24052319
[TBL] [Abstract][Full Text] [Related]
29. An audit of surgical management of gastrointestinal stromal tumours (GIST).
Bucher P; Egger JF; Gervaz P; Ris F; Weintraub D; Villiger P; Buhler LH; Morel P
Eur J Surg Oncol; 2006 Apr; 32(3):310-4. PubMed ID: 16414236
[TBL] [Abstract][Full Text] [Related]
30. Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case.
Ando Y; Tsunoda T; Beck Y; Takayama T; Tahara H
Surg Today; 2005; 35(2):157-60. PubMed ID: 15674500
[TBL] [Abstract][Full Text] [Related]
31. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).
Hohenberger P; Eisenberg B
Ann Surg Oncol; 2010 Oct; 17(10):2585-600. PubMed ID: 20407930
[TBL] [Abstract][Full Text] [Related]
32. [Gastrointestinal stromal tumour: our experience].
Versaci A; Macrì A; Ieni A; Terranova M; Leonello G; Saladino E; Speciale G; Famulari C
Chir Ital; 2009; 61(2):161-9. PubMed ID: 19536989
[TBL] [Abstract][Full Text] [Related]
33. [Imatinib mesylate STI571 therapy for five patients with advanced gastrointestinal stromal tumors].
Shen KT; Hou YY; Qin XY; Song LJ; Sujie A
Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Mar; 8(2):129-31. PubMed ID: 16155822
[TBL] [Abstract][Full Text] [Related]
34. [Successful resection of an advanced gastrointestinal stromal tumor by neoadjuvant chemotherapy with imatinib- a case report].
Nakajima S; Sonoda K; Kadokawa Y; Kawabe A; Yamamoto T
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2645-8. PubMed ID: 20009472
[TBL] [Abstract][Full Text] [Related]
35. Imatinib in gastrointestinal stromal tumors.
Bakshi CA; Jain RA; Sastry PS; Sainani AR; Advani SH
J Assoc Physicians India; 2004 May; 52():403-9. PubMed ID: 15656032
[TBL] [Abstract][Full Text] [Related]
36. [GIST: a clinical case as a model of surgical and pharmacological therapy of solid tumours].
D'Amato A; Pezzoli F; Caterino S; Cavallini M; Balducci G; Bocchetti T; Ziparo V
Chir Ital; 2005; 57(4):509-14. PubMed ID: 16060192
[TBL] [Abstract][Full Text] [Related]
37. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
[TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal stromal tumors treatment in the Imatinib era. The role of fair indication.
Vendettuoli M; Pironi D; Pontone S; Panarese A; La Gioia G; Arcieri S; Romani AM; Palazzini G; Filippini A
Minerva Chir; 2012 Apr; 67(2):165-73. PubMed ID: 22487918
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
[TBL] [Abstract][Full Text] [Related]
40. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
Heinrich MC; Corless CL
J Surg Oncol; 2005 Jun; 90(3):195-207; discussion 207. PubMed ID: 15895440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
